Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. Despite Anktiva's potential, IBRX remains a ...

ImmunityBio, Inc.’s IBRX share price has surged by 20.86%, which has investors questioning if this is right time to sell.

We recently published a list of Top 10 Penny Stocks That Will Skyrocket. In this article, we are going to take a look at ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, invites current and prospective investors to its Investor ...

ImmunityBio, Inc, a leading biotechnology company addressing cancer and infectious diseases by bolstering the natural immune system, announced the US FDA has granted Regenerative Medicine Advanced ...

The FDA granted Regenerative Medicine Advanced Therapy designation for ANKTIVA and CAR-NK therapies to address lymphopenia in patients undergoing chemotherapy or radiation and those with multiply ...

Global submission of marketing authorization applications (MAAs) for the treatment of patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors for ANKTIVA in combination with ...

Cytokine fusion proteins, such as ANKTIVA, represent a novel class of biologics that improve immune responses by enhancing the therapeutic potential of cytokines and promoting lymphocyte ...

The approval of ANKTIVA and the permanent J-code, the trajectory of adoption of ANKTIVA by urologists for BCG unresponsive non-muscle invasive bladder cancer CIS, the authorization of expanded ...